Table 1.
Baseline characteristics of the study population arranged by eventual outcome group on follow up
| Group 0 No admissions Alive at follow up | Group 1 Admitted Alive at follow up | Group 2 Died during follow up | |
|---|---|---|---|
| N | 15 | 11 | 13 |
| Male (n) | 9 | 9 | 11 |
| Age | 70 ± 9 | 67 ± 7 | 68 ± 5 |
| Ischaemic aetiology | 13 | 11 | 11 |
| Non-ischaemic aetiology | 2 | 2 | |
| LVEF (mean ± SD) | 29 ± 5 | 32 ± 4 | 27 ± 7 |
| Therapy (n = treated minimum 1 month at some point) | |||
| Furosemide (n) | 15 | 11 | 13 |
| Thiazide (n) | 3 | 1 | 2 |
| Spironolactone (n) | 2 | 0 | 1 |
| Amiloride (n) | 2 | 2 | 3 |
| ACEI (n) | 15 | 11 | 13 |
| Beta blocker (n) | 8 | 4 | 2 |
| Digoxin (n) | 2 | 2 | 3 |
| Nitrate (n) | 7 | 8 | 4 |
| Calcium channel blocker (n) | 3 | 1 | 0 |
| Aspirin (n) | 12 | 9 | 9 |